Skip to content

EBITDA at other companies

Oric Pharmaceuticals, Inc. logo
Oric Pharmaceuticals, Inc.ORIC
-$39.35M-21.4%
Opko Health logo
Opko HealthOPK
-$28.82M+34.0%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
-$52.98M-147%
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
-$30.39M+28.0%
Erasca, Inc. logo
Erasca, Inc.ERAS
-$187.19M-438%
Eli Lilly logo
Eli LillyLLY

Other financials

Income statement

See full
Operating income-$58.0M-66.3%
Net income-$53.1M-74.7%
EPS (diluted)-$0.52-44.4%

Balance sheet

See full
Cash & equivalents$52.5M+3.8%
Total debt$956.0K-16.7%
Total equity$480.5M+25.3%
Total assets$530.6M+29.5%

Cash flow

See full
Operating cash flow-$46.0M-4.6%
CapEx-
Free cash flow-$34.5M-27.8%

Valuation

See full
Market cap$973.05M+244%
Enterprise value$921.46M+295%

Returns & leverage

See full
Return on equity-42.9%+1.3pp
Debt / equity0.0×
Current ratio10.9×-4.3×

Where this comes from

Calculated from Olema Pharmaceuticals, Inc.’s reported figures.

$58.0Mebit+
$119.0KDepreciation Depletion & Amortization
=-$57.87M

The official record: Olema Pharmaceuticals, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Olema Pharmaceuticals, Inc.'s ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Olema Pharmaceuticals, Inc.'s EBITDA?
Olema Pharmaceuticals, Inc. (OLMA) reported EBITDA of -$57.87M in Q1 2026.
How has Olema Pharmaceuticals, Inc.'s EBITDA changed year-over-year?
Olema Pharmaceuticals, Inc.'s EBITDA decreased by 66.5% year-over-year, from -$34.75M to -$57.87M.
What is the long-term trend for Olema Pharmaceuticals, Inc.'s EBITDA?
Over 4 years (2021 to 2025), Olema Pharmaceuticals, Inc.'s EBITDA has grown at a 25.7% compound annual growth rate (CAGR), from -$71.33M to -$178.21M.
What does EBITDA mean?
Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.